Skip to main content
Premium Trial:

Request an Annual Quote

It's Expensive, So It Must Be Good

Over at Genetic Future, Daniel MacArthur is wondering what everyone wants to know: why buy Navigenics' Annual Insight service for $500 when you can have 23andMe's full genome scan for $100 cheaper? Navigenics recently announced an alternative to its $2,500 genetic testing service, the Annual Insight service, which costs $499 and analyzes genetic predisposition for ten common health conditions, including breast cancer, prostate cancer, colon cancer, and heart disease. However, access is only good for a year. MacArthur definitely isn't going to be the first customer in line. He writes: "Wow, guys, you get to look at a tiny fraction of your own genome for an entire year before your access gets revoked! You also get a whole hour of phone conversation with Navigenics' genetic counselors, which should be more than enough time for them to explain to you that their results have no clinical implications (and indeed the four conditions listed above are diseases where common genetic variants typically have very low predictive power)."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.